|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Study Type: | Interventional |
|---|---|
| Study Design: | Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment |
| Condition: |
Autistic Disorder |
| Interventions: |
Drug: Aripiprazole Drug: Placebo |
Participant Flow
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| No text entered. |
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| No text entered. |
| Description | |
|---|---|
| Placebo | oral placebo once daily (QD) |
| Aripiprazole | oral aripiprazole 2 to 15 mg QD |
| Placebo | Aripiprazole | |
|---|---|---|
| STARTED | 51 | 47 |
| COMPLETED | 36 | 39 |
| NOT COMPLETED | 15 | 8 |
| Lack of Efficacy | 6 | 1 |
| Adverse Event | 3 | 5 |
| Withdrawal by Subject | 2 | 1 |
| Lost to Follow-up | 4 | 1 |
Baseline Characteristics
| Description | |
|---|---|
| Placebo | oral placebo once daily (QD) |
| Aripiprazole | oral aripiprazole 2 to 15 mg QD |
| Placebo | Aripiprazole | Total | |
|---|---|---|---|
|
Number of Participants [units: participants] |
51 | 47 | 98 |
|
Age, Customized [units: participants] |
|||
| 6 to 12 years | 46 | 37 | 83 |
| 13 to 17 years | 5 | 10 | 15 |
|
Gender [units: participants] |
|||
| Female | 7 | 5 | 12 |
| Male | 44 | 42 | 86 |
|
Race/Ethnicity, Customized [units: participants] |
|||
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 7 | 11 | 18 |
| White | 41 | 32 | 73 |
| Other | 3 | 1 | 4 |
|
Race/Ethnicity, Customized [units: participants] |
|||
| Hispanic/Latino | 8 | 6 | 14 |
| Not Hispanic/Latino | 43 | 41 | 84 |
|
Weight Group [units: Participants] |
|||
| <40 kilograms | 32 | 26 | 58 |
| ≥40 kilograms | 19 | 21 | 40 |
|
Body Mass Index [units: kg/cm2] Mean ± Standard Deviation |
19.96 ± 5.392 | 21.08 ± 5.394 | 20.50 ± 5.395 |
|
Height [units: centimeters] Mean ± Standard Deviation |
138.6 ± 14.7 | 140.9 ± 18.80 | 139.7 ± 16.74 |
|
Weight [units: kilograms] Mean ± Standard Deviation |
40.6 ± 18.92 | 43.9 ± 19.15 | 42.2 ± 19.01 |
Outcome Measures
| 1. Primary: | Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score [ Week 8 ] |
| 2. Secondary: | Mean Clinical Global Impressions Improvement Scale (CGI-I) Score [ Week 8 ] |
| 3. Secondary: | Number of Participants With Response at Week 8 [ Week 8 ] |
| 4. Secondary: | Mean Change (Week 8 – Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only) [ Week 8 ] |
| 5. Secondary: | Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores [ Week 8 ] |
| 6. Secondary: | Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S) [ Week 8 ] |
| 7. Secondary: | Summary of Safety [ continuous throughout the study ] |
| 8. Secondary: | Change From Baseline in Body Weight [ Week 8 ] |